Aquinnah Pharmaceuticals

aquinnahpharma.com

Aquinnah Pharmaceuticals is focused on a new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and other neurodegenerative diseases. The medical need for ALS is very high as there are currently no effective treatments for this devastating neurodegenerative disease. ALS progresses rapidly, eventually affecting muscles in the arms, legs, face, diaphragm, and chest. Today, approximately 60% of patients with ALS will not survive beyond three years following diagnosis, with 10% of new patients surviving at least 10 years. Aquinnah Pharmaceuticals has identified lead molecules advancing to clinical studies which are designed to prevent and potentially reverse the pathological stress granules in affected patients. In addition to their use in ALS, these compounds also show promise as a potential treatment for cognition impairment in patients with Alzheimer's disease.